ACP Pushes Premarket Approval for Supplements: What It Means for Your Brand
The American College of Physicians has put the supplement industry on notice. In a formal policy position, the ACP is calling for a comprehensive overhaul of the Dietary Supplement Health and Education Act (DSHEA), the 1994 law that has defined how supplements reach American consumers for three decades. If the ACP's recommendations gain legislative traction, the $60 billion-plus US supplement market would face its most significant structural shift since DSHEA was signed.
For brands operating in sports nutrition, wellness, and functional health, the implications run deep. This isn't a fringe regulatory debate. It's a signal that the operating environment you've built your go-to-market strategy around may be changing faster than most founders and marketing teams expect.
What DSHEA Actually Allows Today
Under current law, supplement brands can bring products to market without demonstrating efficacy or safety to the FDA before launch. The burden of proof runs in reverse: the FDA must show a product is unsafe after the fact to pull it from shelves. Manufacturers are required to notify the FDA of new ingredients, but premarket approval, the kind pharmaceutical companies must obtain, is not required.
That regulatory architecture enabled a market that has grown exponentially. According to survey data, 51% of US adults used dietary supplements in 1999. By 2023, that figure had climbed to 60%. The market is larger, more mainstream, and, as a direct consequence, under more scrutiny than at any point in its modern history.
The ACP argues that the current framework has failed to keep pace with both the scale of consumption and the complexity of products now on the market. That's a hard position to dismiss when the professional body making it represents internal medicine physicians who see the clinical consequences of supplement interactions and adverse events firsthand.
What the ACP Is Specifically Asking For
The ACP's recommendations don't stop at vague calls for reform. They outline a concrete set of requirements that would fundamentally change how brands operate:
- Mandatory evidence-based premarket review. Brands would need to demonstrate safety and, in some cases, efficacy before a product reaches retail shelves or e-commerce channels.
- Product registration. Every supplement would need to be formally registered with the FDA, creating a comprehensive, searchable database of what's actually in the market.
- Strict Good Manufacturing Practice (GMP) compliance across the full supply chain. This extends accountability beyond the brand itself to contract manufacturers, ingredient suppliers, and third-party processors.
Taken together, these measures would raise the cost and timeline of launching a new supplement product significantly. The question for brands isn't whether that's inconvenient. It's whether you're positioned to absorb those costs while your underfunded competitors are not.
The Business Case for Stricter Standards
Here's the counterintuitive read on ACP's push: for established brands with clinical evidence already in hand, stricter premarket requirements could function as a structural competitive moat. If new market entrants suddenly face a 12-to-24-month evidence review process before launch, the white-label operators and fast-follower brands that have competed on price and speed lose their primary advantage.
This dynamic is already playing out in adjacent sectors. Jamieson Wellness's $2 billion takeover bid signals that institutional capital sees long-term value in brands that have built credibility and compliance infrastructure over decades. Acquirers aren't paying premium multiples for generic formulations. They're paying for trust, clinical positioning, and regulatory durability.
The brands that will feel the most pain in a reformed regulatory environment are those that have competed on low barriers to entry. The brands that will benefit are those that have invested in research, manufacturing quality, and transparent labeling practices, because those investments will become table stakes rather than differentiators.
Consumer Demand Is Already Pulling in the Same Direction
The regulatory pressure from the ACP doesn't exist in isolation. The Vitamin Shoppe's 2026 trend report identifies growing consumer demand for third-party certifications and full label transparency as a top-tier purchasing driver. Consumers, particularly in the 25-to-45 demographic that drives the core of the sports nutrition and wellness market, are actively seeking out NSF Certified for Sport, Informed Sport, and USP verification marks before purchasing.
This is the market self-regulating before legislators act. Consumers who've grown up with ingredient tracking apps, personalized nutrition platforms, and wearable health data don't trust marketing claims at face value. They want verification. The $2.1M raise behind Hexis reflects exactly this: investors are backing platforms that connect evidence-based nutrition to measurable outcomes because that's where consumer trust is flowing.
If your brand hasn't already invested in third-party certification and full supply chain transparency, the window to do so proactively, before it becomes a regulatory or market requirement, is narrowing.
What Premarket Approval Would Actually Cost Brands
The economic reality of a stricter premarket framework is worth quantifying honestly. Pharmaceutical-style clinical trials for efficacy can run anywhere from $500,000 to several million dollars per indication, depending on study design and endpoints. Even a streamlined safety review process, modeled on what the ACP is proposing, would likely require significant investment in clinical documentation, toxicology assessments, and legal review before a single unit ships.
For large brands with existing R&D infrastructure and established contract research organization relationships, these costs are manageable. For a startup attempting to enter the creatine or collagen category with a differentiated formulation, they could be prohibitive without venture backing or a licensing arrangement.
Launch timelines would extend accordingly. If you're currently operating on a six-to-eight-month product development cycle from formulation to shelf, a premarket review requirement could push that to 18 months or more. That changes how you manage inventory forecasting, retail buyer conversations, and capital deployment across your product portfolio.
The broader fitness and wellness market is growing fast, as projections pointing to a doubling of the fitness market by 2036 make clear. But faster-growing markets with stricter entry requirements favor brands that can absorb compliance costs, not those that have relied on regulatory arbitrage to stay competitive.
How Supplement Brands Should Be Responding Right Now
Waiting for legislation to pass before adapting is a losing strategy. Regulatory proposals from organizations like the ACP take time to move through Congress, but the consumer and investor signals are already aligned with the direction of travel. Here's how forward-thinking brands are positioning:
- Audit your supply chain for GMP compliance gaps. If your contract manufacturer hasn't passed a third-party GMP audit recently, that's a liability that's getting more expensive to carry.
- Prioritize clinical investment for core SKUs. You don't need to run randomized controlled trials on every product. Identify the two or three products that represent your highest revenue and brand equity, and build the evidence file there first.
- Accelerate third-party certification. NSF, Informed Sport, and USP certifications are already converting into retail buyer preference and consumer trust signals. They're also the closest analog to what premarket review would require.
- Revisit your label claims. Structure/function claims that are aggressive or difficult to substantiate represent regulatory and reputational risk under a stricter framework. Clean them up before a regulator does it for you.
- Incorporate supplement quality into your broader brand narrative. Consumers buying supplements alongside gym memberships and wearables, as explored in the AI-driven wearable market's expansion, are increasingly making integrated health decisions. Your brand story needs to match that sophistication.
The Bigger Picture for the Industry
DSHEA was written in a different era. In 1994, the supplement market was a fraction of its current size, and the products themselves were considerably simpler. The regulatory framework that made sense for a $4 billion market of basic vitamins and minerals is being asked to govern a $60 billion market that includes complex botanical extracts, peptides, and bioactive compounds that didn't exist commercially 30 years ago.
The ACP's push reflects a genuine clinical concern. Physicians are seeing supplement-drug interactions, contamination events, and adverse effects that the current system doesn't have the tools to prevent proactively. That's not a trivial argument, and dismissing it as industry-hostile overreach misses the point.
The supplement brands that will thrive through this regulatory transition are the ones treating compliance not as a cost center but as a brand asset. Third-party verification, clinical evidence, and supply chain integrity are increasingly what separates a trusted wellness brand from a commodity SKU. The ACP's proposal accelerates a market dynamic that was already developing. The only real question is whether you're ahead of it or behind it.
Supplement quality is also directly tied to outcomes that matter to your customers. Consumers who are investing in structured training programs informed by research like the Harvard study linking combined lifting and cardio to reduced mortality risk are making informed decisions about every input in their wellness stack. They expect the supplements they take to meet the same evidence standard as the training protocols they follow. That expectation isn't going away. Regulatory reform or not, the market is moving toward it.